Literature DB >> 19300328

Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus.

Marcus C Robertson1, Florence Murila, Stephen Tong, Lesleigh S Baker, Victor Y Yu, Euan M Wallace.   

Abstract

OBJECTIVE: To investigate whether persistently absent umbilical artery end-diastolic flow in the intrauterine growth-restricted fetus after betamethasone administration is associated with altered perinatal outcomes.
METHODS: This is a retrospective cohort study of 92 pregnancies complicated by intrauterine growth restriction (IUGR) and absent end-diastolic flow in which antenatal betamethasone was given. Predefined maternal outcomes (maternal age, gestational age at diagnosis of absent end-diastolic flow, gestational age at delivery, preexisting medical conditions) and neonatal outcomes (including birth weight; perinatal mortality; duration of neonatal intensive care unit admission; requirement for intubation, assisted ventilation, inotropic support; duration of supplemental oxygen, assisted ventilation; respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage) were analyzed.
RESULTS: Betamethasone administration was associated with a transient return of end-diastolic umbilical artery flow in 58 pregnancies (63%) and persistent absent end-diastolic flow in 34 (37%). Persistent absent end-diastolic flow was seen more frequently in women with prepregnancy medical disorders (59% compared with 24%, P<.001). Neonates from the persistent absent end-diastolic flow subgroup were more likely to require assisted ventilation (93.1% compared with 73.5%, P=.03) and to have longer durations of assisted ventilation (median time 30 days compared with 4 days, P=.03) and supplemental oxygen (median time 45 days compared with 4 days, P=.04).
CONCLUSION: Betamethasone administration is associated with a transient return of end-diastolic flow in two thirds of pregnancies complicated by IUGR and umbilical artery absent end-diastolic flow. Persistent absent end-diastolic flow in the umbilical artery after betamethasone administration may identify a subgroup of fetuses with IUGR at further heightened perinatal risk that, as neonates, are more likely to require assisted ventilation and a longer duration of ventilation and supplemental oxygen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300328     DOI: 10.1097/AOG.0b013e318197bf4d

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

Review 2.  Intrauterine growth restriction: impact on cardiovascular development and function throughout infancy.

Authors:  Emily Cohen; Flora Y Wong; Rosemary S C Horne; Stephanie R Yiallourou
Journal:  Pediatr Res       Date:  2016-02-11       Impact factor: 3.756

3.  Effect of maternal betamethasone administration on feto-placental vascular resistance in the mouse†.

Authors:  Lindsay S Cahill; Clare L Whitehead; Sebastian R Hobson; Greg Stortz; John C Kingdom; Ahmet Baschat; Kellie E Murphy; Lena Serghides; Christopher K Macgowan; John G Sled
Journal:  Biol Reprod       Date:  2019-10-25       Impact factor: 4.285

4.  Sex differences in modulation of fetoplacental vascular resistance in growth-restricted mouse fetuses following betamethasone administration: comparisons with human fetuses.

Authors:  Lindsay S Cahill; Shiri Shinar; Clare L Whitehead; Sebastian R Hobson; Greg Stortz; Viji Ayyathurai; Anjana Ravi Chandran; Anum Rahman; John C Kingdom; Ahmet Baschat; Kellie E Murphy; Lena Serghides; Christopher K Macgowan; John G Sled
Journal:  Am J Obstet Gynecol MFM       Date:  2020-10-06

5.  Judicious use of antenatal glucocorticoids: putting the risks into the balance.

Authors:  J Verhaeghe
Journal:  Facts Views Vis Obgyn       Date:  2011

6.  Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in utero fetal hypoxic status.

Authors:  Clare Whitehead; Wan Tinn Teh; Susan P Walker; Cheryl Leung; Sonali Mendis; Luke Larmour; Stephen Tong
Journal:  BMC Med       Date:  2013-12-09       Impact factor: 8.775

7.  The short term fetal cardiovascular effects of corticosteroids used in obstetrics.

Authors:  Amanda Henry; Antonia Shand; Alec Welsh
Journal:  Australas J Ultrasound Med       Date:  2015-12-31

8.  Dexamethasone on absent end-diastolic flow in umbilical artery, in growth restricted fetuses from early-onset preeclamptic pregnancies and the perinatal outcome.

Authors:  Oana Sorina Tica; Andrei Adrian Tica; Doriana Cojocaru; Mihaela Gheonea; Irina Tica; Dragos Ovidiu Alexandru; Victor Cojocaru; Lucian Cristian Petcu; Vlad Iustin Tica
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

9.  Antenatal corticosteroids and outcomes of preterm small-for-gestational-age neonates in a single medical center.

Authors:  Woo Jeng Kim; Young Sin Han; Hyun Sun Ko; In Yang Park; Jong Chul Shin; Jeong Ha Wie
Journal:  Obstet Gynecol Sci       Date:  2017-12-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.